• Tango Therapeutics President, R&D Crystal Adam sold 27,000 common shares on Sep. 1 at USD 22.37.
• Sale followed the exercise of 27,000 stock options at USD 5.2.
• Directly held common shares fell to 115,743.
• Stock options held rose to 260,040 following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-381853), on September 03, 2026, and is solely responsible for the information contained therein.